Sensititre MYCOTB MIC plate for testing mycobacterium tuberculosis susceptibility to first-And second-Line drugs

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 11-18

  Lee, Jongseok ^a   Armstrong, Derek T ^b   Ssengooba, Willy ^c   Park, Jeong Ae ^a   Yu, Yeuni ^a   Mumbowa, Francis ^c   Namaganda, Carolyn ^c   Mboowa, Gerald ^c   Nakayita, Germine ^c   Armakovitch, Sandra ^d   Chien, Gina ^d   Cho, Sang Nae ^a   Via, Laura E ^e   Barry, Clifton E ^e   Ellner, Jerrold J ^d   Alland, David ^f   Dorman, Susan E ^b   Joloba, Moses L ^c  

^a International Tuberculosis Research Center   (South Korea)

^b University School of Medicine   (United States)

^c MAKERERE UNIVERSITY   (Uganda)

^d BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONTROLLED STUDY; DNA SEQUENCE; DRUG SENSITIVITY; HUMAN; MICROTITER PLATE ASSAY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SOUTH KOREA; UGANDA;

ANTITUBERCULAR AGENTS; ETHAMBUTOL; FLUOROQUINOLONES; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN;

EID: 84891512508     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01209-13     Document Type: Article

References (24)

1. World Health Organization. 2012. Global tuberculosis report. World Health Organization, Geneva, Switzerland.
2. Centers for Disease Control and Prevention. 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MortalMMWRMorb. Mortal. Wkly. Rep. 55:301-305
3. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shanai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. 2010. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 363:1005-1015. http://dx.doi.org/10.1056/NEJMoa0907847
4. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, Gler MT, Blakemore R, Worodria W, Gray C, Huang L, Caceres T, Mehdiyev R, Raymond L, Whitelaw A, Sagadevan K, Alexander H, Albert H, Cobelens F, Cox H, Alland D, Perkins MD. 2011. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377:1495-1505. http://dx.doi.org/10.1016/S0140-6736(11)60438-8
5. Hanrahan CF, Dorman SE, Erasmus L, Koornhof H, Coetzee G, Golub JE. 2012. The impact of expanded testing for multidrug resistant tuberculosis using Genotype MTBDRplus in South Africa: an observational cohort study. PLoS One. 7:e49898. http://dx.doi.org/10.1371/journal.pone.0049898
6. Barnard M, Warren R, Van Pittius NG, van Helden P, Bosman M, Streicher E, Coetzee G, O'Brien R. 2012. GenoType MTBDRsl line probe assay shortens time to diagnosis of extensively drug-resistant tuberculosis in a high-throughput diagnostic laboratory. Am. J. Respir. Crit. Care Med. 186:1298-1305. http://dx.doi.org/10.1164/rccm.201205-0960OC
7. Ramaswamy S, Musser JM. 1998. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber. Lung Dis. 79:3-29. http://dx.doi.org/10.1054/tuld.1998.0002
8. Canetti G, Froman S, Grosset J, Hauduroy P, Langerova M, Mahler HT, Meissner G, Mitchison DA, Sula L. 1963. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull. World Health Organ. 29:565-578.
9. Schön T, Juréen P, Giske CG, Chryssanthou E, Sturegård E, Werngren J, Kahlmeter G, Hoffner SE, Angeby KA. 2009. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J. Antimicrob. Chemother. 64:786-793. http://dx.doi.org/10.1093/jac/dkp262
10. Böttger EC. 2011. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin. Microbiol. Infect. 17:1128-1134. http://dx.doi.org/10.1111/j.1469-0691.2011.03551.x.
11. Nuermberger E, Grosset J. 2004. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur. J. Clin. Microbiol. Infect. Dis. 23:243-255. http://dx.doi.org/10.1007/s10096-004-1109-5.
12. Meier A, Sander P, Schaper KJ, Scholz M, Böttger EC. 1996. Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 40:2452-2454
13. van Soolingen D, de Haas PE, van Doorn HR, Kuijper E, Rinder H, Borgdorff MW. 2000. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J. Infect. Dis. 182:1788-1790. http://dx.doi.org/10.1086/317598
14. Hall L, Jude KP, Clark SL, Dionne K, Merson R, Boyer A, Parrish NM, Wengenack NL. 2012. Evaluation of the Sensititre MycoTB plate for susceptibility testing of the Mycobacterium tuberculosis complex against first- and second-line agents. J. Clin. Microbiol. 50:3732-3734. http://dx.doi.org/10.1128/ JCM.02048-12.
15. Abuali MM, Katariwala R, LaBombardi VJ. 2012. A comparison of the Sensititre MYCOTB panel and the agar proportion method for the susceptibility testing of Mycobacterium tuberculosis. Eur. J. Clin. Microbiol. Infect. Dis. 31:835-839. http://dx.doi.org/10.1007/s10096-011-1382-z
16. Clinical Laboratory Standards Institute. 2003. Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes: approved standard. CLSI document M24-A (ISBN 1-56238-550-3). Clinical Laboratory Standards Institute, Wayne, PA.
17. Takiff HE, Salazar L, Guerrero C, Philipp W, Huang WM, Kreiswirth B, Cole ST, Jacobs WR, Jr, Telenti A. 1994. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents Chemother. 38:773-780. http://dx.doi.org/10.1128/AAC.38.4.773
18. Madison B, Robinson-Dunn B, George I, Gross W, Lipman H, Metchock B, Sloutsky A, Washabaugh G, Mazurek G, Ridderhof J. 2002. Multicenter evaluation of ethambutol susceptibility testing of Mycobacterium tuberculosis by agar proportion and radiometric methods. J. Clin. Microbiol. 40:3976-3979. http://dx.doi.org/10.1128/JCM.40.11.3976-3979.2002.
19. Angra PK, Taylor TH, Iademarco MF, Metchock B, Astles JR, Ridderhof JC. 2012. Performance of tuberculosis drug susceptibility testing in U.S. laboratories from 1994 to 2008. J. Clin. Microbiol. 50:1233-1239. http://dx.doi.org/10.1128/JCM.06479-11.
20. Ängeby K, Juréen P, Kahlmeter G, Hoffner SE, Schön T. 2012. Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull. World Health Organ 90:693-698. http://dx.doi.org/10.2471/BLT.11.096644.
21. Calver AD, Falmer AA, Murray M, Strauss OJ, Streicher EM, Hanekom M, Liversage T, Masibi M, van Helden PD, Warren RM, Victor TC. 2010. Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg. Infect. Dis. 16:267-271. http://dx.doi.org/10.3201/eid1602.090968
22. Cox HS, Sibilia K, Feuerriegel S, Kalon S, Polonsky J, Khamraev AK, Rusch-Gerdes S, Mills C, Niemann S. 2008. Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis. N. Engl. J. Med. 359:2398-2400. http://dx.doi.org/10.1056/NEJMc0805644
23. Babalik A, Babalik A, Mannix S, Francis D, Menzies D. 2011. Therapeutic drug monitoring in the treatment of active tuberculosis. Can. Respir. J. 18:225-229
24. World Health Organization. 2012. Tuberculosis laboratory biosafety manual. WHO/HTM/TB/2012.11. World Health Organization, Geneva, Switzerland Diseases